Status:
ACTIVE_NOT_RECRUITING
A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-49 years
Phase:
PHASE1
Brief Summary
The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- Is in good health before randomization
- Exclusion Criteria:
- Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination.
- Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
Exclusion
Key Trial Info
Start Date :
September 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 16 2025
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT06611033
Start Date
September 25 2024
End Date
December 16 2025
Last Update
November 25 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Velocity Clinical Research, Hallandale Beach ( Site 0003)
Hallandale, Florida, United States, 33009
2
Research Centers of America ( Hollywood ) ( Site 0002)
Hollywood, Florida, United States, 33024
3
University of Texas Medical Branch ( Site 0001)
Galveston, Texas, United States, 77555-1115